
|Articles|July 20, 2015
Dr. Verma on Palbociclib Plus Fulvestrant for HR+/HER2- Breast Cancer
Author(s)Sunil Verma, MD, MSEd, FRCPC
Sunil Verma, MD, MSEd, FRCPC, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.
Advertisement
Sunil Verma, MD, MSEd, FRCPC, medical director, Louise Temerty Breast Cancer Centre at Sunnybrook Health Sciences Centre, discusses the PALOMA-3 trial, which examined palbociclib with or without fulvestrant for the treatment of patients with HR-positive, HER2-negative breast cancer.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Tentative Approval to Generic Olaparib Tablets
2
Study Reports 10-Year Outcomes of Focal Therapy for Prostate Cancer
3
GU Oncology Trial Logistics: Nursing Insights from Dana-Farber
4
Optimizing Multiple Myeloma Care: Insights From a Nursing Expert
5






















































